More recently, cyclin D/cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) have shown to be effective in overcoming endocrine resistance and are used in combination with endocrine therapy to increase the survival advantage of metastatic ER+ BC patients78. The gene discussed is CDK4; the disease is breast cancer.